Abstract:The ongoing coronavirus disease 2019 (COVID-19) is a pandemic causing millions of deaths, devastating social and economic disruptions. Testing individuals for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of COVID-19, is critical for mitigating and containing COVID-19. Many countries are implementing group testing strategies against COVID-19 to improve testing capacity and efficiency while saving required workloads and consumables. A group of individuals’ nasopharyngeal/oropharyngeal (NP/OP) swab samples is mixed to conduct one test. However, existing group testing methods neglect the fact that mixing samples usually leads to substantial dilution of viral ribonucleic acid (RNA) of SARS-CoV-2, which seriously impacts the sensitivity of tests. In this paper, we aim to screen individuals infected with COVID-19 with as few tests as possible, under the premise that the sensitivity of tests is high enough. To achieve this goal, we propose an Adaptive Group Testing (AdaGT) method. By collecting information on the number of positive and negative samples that have been identified during the screening process, the AdaGT method can estimate the ratio of positive samples in real-time. Based on this ratio, the AdaGT algorithm adjusts its testing strategy adaptively between an individual testing strategy and a group testing strategy. The group size of the group testing strategy is carefully selected to guarantee that the sensitivity of each test is higher than a predetermined threshold and that this group contains at most one positive sample on average. Theoretical performance analysis on the AdaGT algorithm is provided and then validated in experiments. Experimental results also show that the AdaGT algorithm outperforms existing methods in terms of efficiency and sensitivity. Note to Practitioners—Real-time reverse transcription-polymerase chain reaction (rRT-PCR) tests provide scope for automation and are one of the most widely used laboratory methods for detecting the SARS-CoV-2 virus. This paper is motivated by the following challenges: (1) Many countries are experiencing an acute shortage of professionals and consumables for conducting rRT-PCR tests; (2) Group sizes of existing group testing methods against COVID-19 may not be optimal, which adversely impacts the efficiency of the screening of the SARS-CoV-2 virus; (3) Existing group testing methods do not consider the fact that the sensitivity of rRT-PCR tests usually decreases with the group size. The objective of this paper is to improve the efficiency and sensitivity of large-scale screening against COVID-19. For achieving this goal, we propose an Adaptive Group Testing (AdaGT) algorithm, which has the following advantages: (1) It can improve the efficiency for screening the SARS-CoV-2 virus, mainly by adaptively adjusting its testing strategy between an individual testing strategy and a group testing strategy based upon an estimated ratio of positive samples during the screening process; (2) It can guarantee a high sensitivity of the rRT-PCR tests by determining the group sizes of the group testing strategy based upon some constraints; (3) We derive an appropriate threshold for the estimated ratio of positive samples such that the AdaGT algorithm can achieve a minimum average number of rRT-PCR tests and can be directly employed in practical applications.

An Algorithmic Approach to the Use of Rapid Molecular Diagnostics for SARS-CoV-2, Influenza Viruses, and Other Respiratory Pathogens During an Unprecedented Respiratory Season

Group Testing for SARS-CoV-2 Allows for Up to 10-Fold Efficiency Increase Across Realistic Scenarios and Testing Strategies

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

Rapid Development and Validation of a Novel Laboratory-Derived Test for the Detection of SARS-CoV-2

Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: A systematic literature review

Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample

Changes in use of multiplex respiratory panel testing during the COVID-19 pandemic

Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests

The impact of commercial rapid respiratory virus diagnostic tests on patient outcomes and health system utilization

Routine Laboratory Blood Tests Predict SARS-CoV-2 Infection Using Machine Learning

Impact of Socio-Economic Status on Age at Menarche

Rapid Antigen Test Combine with Nucleic Acid Detection: A Better Strategy for COVID-19 Screening at Points of Entry

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

Reducing Diagnostic Bias Through Multiplex Polymerase Chain Reaction (PCR) Testing for SARS-CoV-2, Influenza A/B, and RSV

Distinct Laboratory Test Result Profiles Between SARS-CoV-2 and Seasonable Influenza Infected Patients

A-272 Evaluation of a Real-Time Multiplex Polymerase Chain Reaction Assay for Simultaneous Detection of Respiratory Pathogens in Nasopharyngeal Specimens

Internationally standardized respiratory viral load testing with limited resources: A derivative‐of‐care calibration strategy for SARS‐CoV‐2

AdaGT: An Adaptive Group Testing Method for Improving Efficiency and Sensitivity of Large-Scale Screening Against COVID-19

Clinical evaluation of the Roche distributed SD Biosensor SARS-CoV-2 & Flu A/B Rapid Antigen Test amongst mild symptomatic people during the 2022/2023 winter season